Roche’s AD study shows rapid clearance of amyloid plaques
Roche has shared new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada.
Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle Alzheimer’s disease (AD) study and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer’s disease, with initiation planned later this year.
As part of its growing Alzheimer’s development programme, Roche also announced its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer’s disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages.
“Alzheimer’s disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “Trontinemab is designed to target a key driver of Alzheimer’s disease biology more effectively in the brain.
“Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer’s disease, we are advancing science with the goal of delaying —and ultimately preventing—progression of this devastating condition.”
New data on trontinemab
Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer’s disease.
Roche’s Brainshuttle technology combines an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module.
New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8mg/kg and 3.6mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET).
In the 3.6mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants after 28 weeks of treatment; 72% achieved deep clearance below 11 centiloids.
These data were reinforced by early and significant reductions in fluid biomarkers of AD, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and plasma.
Diana Turner, Senior Digital Content Editor, DDW
